Lykos’ MD­MA ther­a­py to go be­fore FDA com­mit­tee; GSK ex­pands work with BioVer­sys

Plus, news about Ele­don and Tra­vere Ther­a­peu­tics:

Lykos Ther­a­peu­tics’ MD­MA ther­a­py gets an ad­comm date: An FDA ad­vi­so­ry com­mit­tee is sched­uled to meet June 4 to weigh the ben­e­fits and risks of the biotech’s NDA for its mido­mafe­t­a­mine (MD­MA) cap­sules in com­bi­na­tion with psy­cho­log­i­cal in­ter­ven­tion for adults with post-trau­mat­ic stress dis­or­der (PTSD). This will be the first ad­comm meet­ing to re­view a new PTSD treat­ment in 25 years. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER